The National Institutes of Health (NIH) has issued a Phase II Small Business Innovation Research (SBIR) grant to biopharmaceutical company GMSBiotech, Inc. (GMS)—creator of novel microarraybased diagnostic solutions for personalized medicine, and subcontractor Pure Protein, L.L.C. (Pure Protein)—a leader in soluble Human Leukocyte Antigen (HLA) reagents production and application development, to co-develop and deploy a diagnostic assay for organ transplant patients.